Detroit 562 cells were purchased from ATCC and cultured in RPMI medium (Gibco) supplemented with 10% fetal bovine serum performance (Gibco), 100 U/ml penicillin and 100μg/ml streptomycin (Gibco), and 1 mM sodium pyruvate (Gibco). LPS from E.coli B4:111 (Sigma) at 1 μg/mL was used to stimulate the cells. Inhibition of NF-kB was done treating the cells with BAY 11–7082 (ChemCruz) at 100uM (stock solution at 50 mM in DMSO) for one hour prior and at 90uM (dilution 9/10 in the medium containing the ligand) during the LPS treatment (Fig. 4 b and c). RELA activation assay, RT-qPCR and ChIP-qPCR procedures are described in Additional file 11 .
Lps from e coli b4 111
Manufactured by Merck Group
LPS from E.coli B4:111 is a laboratory reagent derived from the lipopolysaccharide of the Escherichia coli bacterial strain B4:111. It is used in scientific research applications.
Automatically generated - may contain errors
Lab products found in correlation
Fetal bovine serum performance, by Thermo Fisher Scientific (2 mentions)
Bay11 7082, by Santa Cruz Biotechnology (2 mentions)
Sodium pyruvate, by Thermo Fisher Scientific (2 mentions)
Streptomycin, by Thermo Fisher Scientific (2 mentions)
Penicillin, by Thermo Fisher Scientific (2 mentions)
Rpmi medium, by Thermo Fisher Scientific (2 mentions)
Fadu cell, by American Type Culture Collection (1 mentions)
2 protocols using lps from e coli b4 111
1
NF-kB Inhibition Assay in Detroit 562 Cells
2
FaDu Cell Stimulation and NFKB Inhibition
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
FaDu cells were purchased from ATCC and cultured in RPMI medium (Gibco) supplemented with 10% fetal bovine serum performance (Gibco), 100 U/ml penicillin and 100 ug/ml streptomycin (Gibco), and 1 mM sodium pyruvate (Gibco). LPS from E. coli B4:111 (Sigma) at 1 μg/mL was used to stimulate the cells. Inhibition of NFKB was achieved using BAY 11–7082 (ChemCruz) at 50 uM (stock solution at 50 mM in DMSO) for one hour prior and at 45 uM (dilution 9/10 in the medium containing the ligand) during the treatment. RELA activation as well as gene expression were performed as described in Supplementary Table S7 .
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!